サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：HIV治療薬の世界市場：市場規模 - 薬物クラス別、投与方法別、流通チャネル別、地域別展望、競合戦略、セグメント別予測（～2032年）
市場調査レポート
商品コード
1174975

HIV治療薬の世界市場：市場規模 - 薬物クラス別、投与方法別、流通チャネル別、地域別展望、競合戦略、セグメント別予測（～2032年）

HIV Drugs Market Size- By Drug Class, By Administration, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日: | 発行: SPER Market Research Pvt. Ltd. | ページ情報: 英文 232 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
HIV治療薬の世界市場：市場規模 - 薬物クラス別、投与方法別、流通チャネル別、地域別展望、競合戦略、セグメント別予測（～2032年）
出版日: 2022年12月02日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 232 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界のHIV治療薬の市場規模は、2032年までに4,974万米ドルに達し、CAGRで4.05％の成長が予測されています。

HIVの感染率と診断数の増加は、世界市場の成長を牽引する重要な要因の一つです。原因、症状、治療法に関する国民の知識を高めることを目的とした政府活動の増加も、市場に影響を与えています。

当レポートでは、世界のHIV治療薬市場について調査し、市場力学、市場変数と展望、薬物クラス・投与方法・流通チャネル・地域別の市場分析、企業プロファイル等に関する情報を提供しています。

目次

第1章 イントロダクション

  • 調査範囲
  • 市場セグメント分析

第2章 調査手法

  • 調査データソース
  • 市場規模の推定
  • データの三角測量

第3章 エグゼクティブサマリー

第4章 市場力学

  • 促進要因、抑制要因、機会、課題の分析
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 世界のHIV治療薬市場におけるCOVID-19の影響

第5章 市場変数と展望

  • SWOT分析
    • 強み
    • 弱み
    • 機会
    • 脅威
  • PESTEL分析
    • 政治情勢
    • 経済情勢
    • 社会情勢
    • 技術情勢
    • 環境情勢
    • 法的情勢
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入者の脅威
    • 競合企業間の敵対関係
  • ヒートマップ分析

第6章 世界のHIV治療薬市場：薬物クラス別（2019年～2032年（100万米ドル））

  • ケモカイン受容体阻害剤
  • エントリー阻害剤 - CCR5共受容体拮抗剤
  • 融合阻害剤
  • インテグレート阻害剤、HIVインテグラーゼ鎖状物輸送阻害剤
  • マルチクラスコンビネーション製品、プロテアーゼ阻害剤
  • 非ヌクレオシド系逆転写酵素阻害剤（NNRT)
  • ヌクレオシド系逆転写酵素阻害剤（NRT)

第7章 世界のHIV治療薬市場：投与方法別（2019年～2032年（100万米ドル））

  • 経口
  • 非経口

第8章 世界のHIV治療薬市場：流通チャネル別（2019年～2032年（100万米ドル））

  • 病院薬局
  • オンライン薬局
  • 小売薬局
  • その他

第9章 世界のHIV治療薬市場：地域別（2019年～2032年（100万米ドル））

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他のアジア太平洋
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • 中東・アフリカ
    • サウジアラビア王国
    • アラブ首長国連邦
    • その他の中東・アフリカ

第10章 企業プロファイル

  • Abbvie Inc.
    • 企業概要
    • 財務展望
    • 製品概要
    • 最近の開発
  • Aelix Therapeutics
  • AIM ImmunoTech
  • BioNTech
  • Biosantech
  • Boehringer Ingelheim International GmbH
  • Bristrol-Myers Squibb Company
  • CytoDyn
  • Dewpoint Therapeutics
  • Gilead Sciences
  • GlaxoSmithKline
  • ImmunityBio
  • Janssen Pharmaceuticals
  • Japan Tobacco
  • Merck
  • Mylan
  • Roche
  • Shionogi
  • Starpharma
  • TaiMed Biologics
  • Theratechnologies
  • ViiV Heathcare
目次
Product Code: PHAR2213

Global HIV Drugs Market Overview:

According to SPER Market Research, the Global HIV Drugs Market is estimated to reach USD 49.74 million by 2032 with a CAGR of 4.05%.

The chronic and potentially fatal human immunodeficiency virus (HIV) can be spread to humans to another through sexual contact and blood-to-blood contact. It is a virus that targets CD-4 cells, which are immunological cells, rendering the body more vulnerable to infections and other disorders. The demand for HIV medications has benefited from the increasing incidence of HIV illness throughout time. HIV medications assist in inhibiting HIV replication, hence lowering the risk of transmission. The increase in HIV prevalence and its diagnosis is one of the key reasons driving the growth of the worldwide market for HIV medications. In addition, a growth in the number of government activities aimed at raising public knowledge of causes, symptoms, and treatments has an impact on the market. The availability of generic medications, which are as effective and chemically equivalent to branded medications, is another factor influencing the demand for HIV medications.

Impact of COVID-19 on the Global HIV Drugs Market

Global healthcare goods import, and export have been hampered by the COVID-19 epidemic. Because of the disruption and volatility in the medicine supply, the pandemic has had a negative effect on the growth of this industry. Additionally, the demand for antiretroviral and antibiotic drugs has decreased internationally due to the decline in the number of new patient prescriptions in the United States, Europe, and other COVID-affected areas and nations. The majority of businesses have seen a negative effect of the epidemic on the sales of HIV/AIDS medications.

Scope of the Report:

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Drug Class, By Administration, By Distribution Channel
  • Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
  • Companies Covered: Abbvie Inc., Aelix Therapeutics, AIM ImmunoTech, BioNTech, Biosantech, Boehringer Ingelheim International GmbH, Bristrol-Myers Squibb Company, CytoDyn, Dewpoint Therapeutics, Gilead Sciences, GlaxoSmithKline, ImmunityBio, Janssen Pharmaceuticals, Japan Tobacco, Merck, Mylan, Roche, Shionogi, Starpharma, TaiMed Biologics, Theratechnologies, ViiV Healthcare.

Global HIV Drugs Market Segmentation:

  • By Drug Class: Based on the Drug Class, Global HIV Drugs Market is segmented as; Chemokine Receptor Inhibitors, Entry Inhibitors - CCR5 Co-Receptor Antagonist, Fusion Inhibitors, Integrate Inhibitors, HIV Integrase Strand Transfer Inhibitors, Multi-Class Combination Products, Protease Inhibitors, Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's), Nucleoside Reverse Transcriptase Inhibitors (NRT's).
  • By Administration: Based on the Administration, Global HIV Drugs Market is segmented as; Oral, Parenteral.
  • By Distribution Channel: Based on the Distribution Channel, Global HIV Drugs Market is segmented as; Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Others.
  • By Region: The worldwide market may be divided into three regions based on geography: North America, Europe, and the rest of the world. It is expected that North America would predominate. The rising incidence of HIV infection among Americans is to blame for this region's dominance. The demand for HIV medications is greatly increased by a large patient base. The population's awareness is another element influencing the progress of the region. Additionally, the existence of major companies that provide cutting-edge HIV medications for the treatment of HIV infection will further accelerate market expansion. Rapid increase in the number of HIV infections and the abundance of HIV medicine manufacturers in this area, Europe is anticipated to be the second-largest market throughout the projection period.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global HIV Drugs Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global HIV Drugs Market, By Drug Class, 2019-2032 (USD Million)

  • 6.1. Chemokine Receptor Inhibitors
  • 6.2. Entry Inhibitors - CCR5 Co-Receptor Antagonist
  • 6.3. Fusion Inhibitors
  • 6.4. Integrate Inhibitors, HIV Integrase Strand Transfer Inhibitors
  • 6.5. Multi-Class Combination Products, Protease Inhibitors
  • 6.6. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
  • 6.7. Nucleoside Reverse Transcriptase Inhibitors (NRT's)

7. Global HIV Drugs Market, By Administration, 2019-2032 (USD Million)

  • 7.1. Oral
  • 7.2. Parenteral

8. Global HIV Drugs Market, By Distribution Channel, 2019-2032 (USD Million)

  • 8.1. Hospital Pharmacies
  • 8.2. Online Pharmacies
  • 8.3. Others
  • 8.4. Retail Pharmacies

9. Global HIV Drugs Market, By Region, 2019-2032 (USD Million)

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 United Kingdom
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 Australia
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Rest of South America
  • 9.5 Middle East & Africa
    • 9.5.1 Kingdom of Saudi Arabia
    • 9.5.2 United Arab Emirates
    • 9.5.3 Rest of Middle East & Africa

10. Company Profiles

  • 10.1 Abbvie Inc.
    • 10.1.1 Company details
    • 10.1.2 Financial outlook
    • 10.1.3 Product summary
    • 10.1.4 Recent developments
  • 10.2 Aelix Therapeutics
    • 10.2.1 Company details
    • 10.2.2 Financial outlook
    • 10.2.3 Product summary
    • 10.2.4 Recent developments
  • 10.3 AIM ImmunoTech
    • 10.3.1 Company details
    • 10.3.2 Financial outlook
    • 10.3.3 Product summary
    • 10.3.4 Recent developments
  • 10.4 BioNTech
    • 10.4.1 Company details
    • 10.4.2 Financial outlook
    • 10.4.3 Product summary
    • 10.4.4 Recent developments
  • 10.5 Biosantech
    • 10.5.1 Company details
    • 10.5.2 Financial outlook
    • 10.5.3 Product summary
    • 10.5.4 Recent developments
  • 10.6 Boehringer Ingelheim International GmbH
    • 10.6.1 Company details
    • 10.6.2 Financial outlook
    • 10.6.3 Product summary
    • 10.6.4 Recent developments
  • 10.7 Bristrol-Myers Squibb Company
    • 10.7.1 Company details
    • 10.7.2 Financial outlook
    • 10.7.3 Product summary
    • 10.7.4 Recent developments
  • 10.8 CytoDyn
    • 10.8.1 Company details
    • 10.8.2 Financial outlook
    • 10.8.3 Product summary
    • 10.8.4 Recent developments
  • 10.9 Dewpoint Therapeutics
    • 10.9.1 Company details
    • 10.9.2 Financial outlook
    • 10.9.3 Product summary
    • 10.9.4 Recent developments
  • 10.10 Gilead Sciences
    • 10.10.1 Company details
    • 10.10.2 Financial outlook
    • 10.10.3 Product summary
    • 10.10.4 Recent developments
  • 10.11 GlaxoSmithKline
    • 10.11.1 Company details
    • 10.11.2 Financial outlook
    • 10.11.3 Product summary
    • 10.11.4 Recent developments
  • 10.12 ImmunityBio
    • 10.12.1 Company details
    • 10.12.2 Financial outlook
    • 10.12.3 Product summary
    • 10.12.4 Recent developments
  • 10.13 Janssen Pharmaceuticals
    • 10.13.1 Company details
    • 10.13.2 Financial outlook
    • 10.13.3 Product summary
    • 10.13.4 Recent developments
  • 10.14 Japan Tobacco
    • 10.14.1 Company details
    • 10.14.2 Financial outlook
    • 10.14.3 Product summary
    • 10.14.4 Recent developments
  • 10.15 Merck
    • 10.15.1 Company details
    • 10.15.2 Financial outlook
    • 10.15.3 Product summary
    • 10.15.4 Recent developments
  • 10.16 Mylan
    • 10.16.1 Company details
    • 10.16.2 Financial outlook
    • 10.16.3 Product summary
    • 10.16.4 Recent developments
  • 10.17 Roche
    • 10.17.1 Company details
    • 10.17.2 Financial outlook
    • 10.17.3 Product summary
    • 10.17.4 Recent developments
  • 10.18 Shionogi
    • 10.18.1 Company details
    • 10.18.2 Financial outlook
    • 10.18.3 Product summary
    • 10.18.4 Recent developments
  • 10.19 Starpharma
    • 10.19.1 Company details
    • 10.19.2 Financial outlook
    • 10.19.3 Product summary
    • 10.19.4 Recent developments
  • 10.20 TaiMed Biologics
    • 10.20.1 Company details
    • 10.20.2 Financial outlook
    • 10.20.3 Product summary
    • 10.20.4 Recent developments
  • 10.21 Theratechnologies
    • 10.21.1 Company details
    • 10.21.2 Financial outlook
    • 10.21.3 Product summary
    • 10.21.4 Recent developments
  • 10.22 ViiV Heathcare
    • 10.22.1 Company details
    • 10.22.2 Financial outlook
    • 10.22.3 Product summary
    • 10.22.4 Recent developments